CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5′(1′)iminium ion

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Nicotine, the major addictive agent in tobacco, is metabolized primarily by CYP2A6-catalyzed oxidation. The product of this reaction, 5′- hydroxynicotine, is in equilibrium with the nicotine Δ 5′(1′)iminium ion and is further metabolized to cotinine. We reported previously that both CYP2A6 and the closely related extrahepatic enzyme CYP2A13 were inactivated during nicotine metabolism; however, inactivation occurred after metabolism was complete. This led to the hypothesis that oxidation of a nicotine metabolite, possibly the nicotine Δ5′(1′)iminium ion, was responsible for generating the inactivating species. In the studies presented here, we confirm that the nicotine Δ5′(1′)iminium ion is an inactivator of both CYP2A6 and CYP2A13, and inactivation depends on time, concentration, and the presence of NADPH. Inactivation was not reversible and was accompanied by a parallel loss in spectrally active protein, as measured by reduced CO spectra. These data are consistent with the characterization of the nicotine Δ5′(1′)iminium ion as a mechanism-based inactivator of both CYP2A13 and CYP2A6. We also confirm that both CYP2A6 and CYP2A13 catalyze the metabolism of the nicotine Δ 5′(1′)iminium ion to cotinine and provide evidence that both enzymes catalyze the sequential metabolism of the nicotine Δ5′(1′)iminium ion. That is, a fraction of the cotinine formed may not be released from the enzyme before further oxidation to 3′-hydroxycotinine.

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume343
Issue number2
DOIs
StatePublished - Nov 1 2012

Fingerprint

Nicotine
Ions
Cotinine
Enzymes
Carbon Monoxide
NADP
Tobacco

Cite this

CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5′(1′)iminium ion. / von Weymarn, Linda B; Retzlaff, Cassandra; Murphy, Sharon E.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 343, No. 2, 01.11.2012, p. 307-315.

Research output: Contribution to journalArticle

@article{c874227050aa4dd2b0dd704736ba48fa,
title = "CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5′(1′)iminium ion",
abstract = "Nicotine, the major addictive agent in tobacco, is metabolized primarily by CYP2A6-catalyzed oxidation. The product of this reaction, 5′- hydroxynicotine, is in equilibrium with the nicotine Δ 5′(1′)iminium ion and is further metabolized to cotinine. We reported previously that both CYP2A6 and the closely related extrahepatic enzyme CYP2A13 were inactivated during nicotine metabolism; however, inactivation occurred after metabolism was complete. This led to the hypothesis that oxidation of a nicotine metabolite, possibly the nicotine Δ5′(1′)iminium ion, was responsible for generating the inactivating species. In the studies presented here, we confirm that the nicotine Δ5′(1′)iminium ion is an inactivator of both CYP2A6 and CYP2A13, and inactivation depends on time, concentration, and the presence of NADPH. Inactivation was not reversible and was accompanied by a parallel loss in spectrally active protein, as measured by reduced CO spectra. These data are consistent with the characterization of the nicotine Δ5′(1′)iminium ion as a mechanism-based inactivator of both CYP2A13 and CYP2A6. We also confirm that both CYP2A6 and CYP2A13 catalyze the metabolism of the nicotine Δ 5′(1′)iminium ion to cotinine and provide evidence that both enzymes catalyze the sequential metabolism of the nicotine Δ5′(1′)iminium ion. That is, a fraction of the cotinine formed may not be released from the enzyme before further oxidation to 3′-hydroxycotinine.",
author = "{von Weymarn}, {Linda B} and Cassandra Retzlaff and Murphy, {Sharon E}",
year = "2012",
month = "11",
day = "1",
doi = "10.1124/jpet.112.195255",
language = "English (US)",
volume = "343",
pages = "307--315",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5′(1′)iminium ion

AU - von Weymarn, Linda B

AU - Retzlaff, Cassandra

AU - Murphy, Sharon E

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Nicotine, the major addictive agent in tobacco, is metabolized primarily by CYP2A6-catalyzed oxidation. The product of this reaction, 5′- hydroxynicotine, is in equilibrium with the nicotine Δ 5′(1′)iminium ion and is further metabolized to cotinine. We reported previously that both CYP2A6 and the closely related extrahepatic enzyme CYP2A13 were inactivated during nicotine metabolism; however, inactivation occurred after metabolism was complete. This led to the hypothesis that oxidation of a nicotine metabolite, possibly the nicotine Δ5′(1′)iminium ion, was responsible for generating the inactivating species. In the studies presented here, we confirm that the nicotine Δ5′(1′)iminium ion is an inactivator of both CYP2A6 and CYP2A13, and inactivation depends on time, concentration, and the presence of NADPH. Inactivation was not reversible and was accompanied by a parallel loss in spectrally active protein, as measured by reduced CO spectra. These data are consistent with the characterization of the nicotine Δ5′(1′)iminium ion as a mechanism-based inactivator of both CYP2A13 and CYP2A6. We also confirm that both CYP2A6 and CYP2A13 catalyze the metabolism of the nicotine Δ 5′(1′)iminium ion to cotinine and provide evidence that both enzymes catalyze the sequential metabolism of the nicotine Δ5′(1′)iminium ion. That is, a fraction of the cotinine formed may not be released from the enzyme before further oxidation to 3′-hydroxycotinine.

AB - Nicotine, the major addictive agent in tobacco, is metabolized primarily by CYP2A6-catalyzed oxidation. The product of this reaction, 5′- hydroxynicotine, is in equilibrium with the nicotine Δ 5′(1′)iminium ion and is further metabolized to cotinine. We reported previously that both CYP2A6 and the closely related extrahepatic enzyme CYP2A13 were inactivated during nicotine metabolism; however, inactivation occurred after metabolism was complete. This led to the hypothesis that oxidation of a nicotine metabolite, possibly the nicotine Δ5′(1′)iminium ion, was responsible for generating the inactivating species. In the studies presented here, we confirm that the nicotine Δ5′(1′)iminium ion is an inactivator of both CYP2A6 and CYP2A13, and inactivation depends on time, concentration, and the presence of NADPH. Inactivation was not reversible and was accompanied by a parallel loss in spectrally active protein, as measured by reduced CO spectra. These data are consistent with the characterization of the nicotine Δ5′(1′)iminium ion as a mechanism-based inactivator of both CYP2A13 and CYP2A6. We also confirm that both CYP2A6 and CYP2A13 catalyze the metabolism of the nicotine Δ 5′(1′)iminium ion to cotinine and provide evidence that both enzymes catalyze the sequential metabolism of the nicotine Δ5′(1′)iminium ion. That is, a fraction of the cotinine formed may not be released from the enzyme before further oxidation to 3′-hydroxycotinine.

UR - http://www.scopus.com/inward/record.url?scp=84867603666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867603666&partnerID=8YFLogxK

U2 - 10.1124/jpet.112.195255

DO - 10.1124/jpet.112.195255

M3 - Article

VL - 343

SP - 307

EP - 315

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -